Benefits
Skin water and oil content (supplier registry report, not cited here)
The supplier describes a registry study in 67 healthy women taking 300 mg a day for 4 weeks, reporting increases in skin water and oil content and fewer exfoliating cells. That study is not among this page's references, so it cannot be checked, and by its own description the women chose their own group rather than being randomly assigned and there was no placebo. Treat it as a company claim, not verified evidence.
Oral UV protection: no study of this is cited here
The supplier says oral Opextan reduced skin sensitivity to UV light, measured as a change in the minimal erythemal dose. No such study appears in this page's references, so there is no way to check the size of the effect, how many people took part, or whether there was a comparison group. Nothing here shows that Opextan protects skin from sun damage, and it is not a substitute for sunscreen.
Verbascoside, the standardised active (laboratory antioxidant work only)
Verbascoside is a polyphenol that scavenges free radicals in laboratory tests. In one cell-culture study it protected human keratinocytes from UV-C damage more effectively than quercetin or rutin (PMID 18404597), and a formulation-chemistry paper measured its antioxidant activity and stability in cosmetic preparations (PMID 21852765). The claim that it is the most powerful antioxidant in olive oil, or 5 times more active than hydroxytyrosol and tyrosol, has no citation on this page. Antioxidant activity in a dish does not mean an antioxidant effect in the body.
Lipid peroxidation: topical and cell-culture work only
The supplier reports reduced lipid peroxidation when Opextan was applied to the skin. That is a topical result, not an oral one, and the study behind it is not cited here. The related cited work is cell culture: verbascoside combined with oleuropein and hydroxytyrosol reduced markers of oxidative damage, inflammation and collagen breakdown in UVB-exposed human skin cells in a dish (PMID 41266576). Rubbing something on the skin tells you nothing about what a capsule does, and neither result was measured in a living person.
Wrinkle prevention has not been tested in people here
Nothing on this page proves that Opextan prevents wrinkles. No cited study measured wrinkles in anyone. The nearest evidence is a cell-culture experiment in which verbascoside, oleuropein and hydroxytyrosol reduced collagen-degradation and inflammatory gene activity in UVB-exposed human skin cells in a dish (PMID 41266576). That is a plausible starting point for research, not a demonstrated effect on human skin.
Blood sugar: 15-person supplier study, not cited here
The supplier describes a 12-week study of olive pulp extract in 15 people with impaired blood sugar control, reporting lower fasting glucose. That study is not cited anywhere on this page, so its design, dose and results cannot be checked, and 15 people is a very small group. Research done in people with a blood sugar problem does not show what an extract does for a healthy person, and no supplement should be taken to treat or prevent diabetes.
Heart health: no cited study measured it
Olives and olive oil are a staple of the Mediterranean diet, which has been studied for heart health as a whole eating pattern. That says nothing about a concentrated olive extract in a capsule. None of the cited references measured blood pressure, cholesterol or any other heart-related outcome, in people or otherwise, and Opextan should not be taken to prevent heart disease.
Developed with a cosmetics company (business background, not a benefit)
Opextan was co-developed by Indena and Kanebo Cosmetics. That is a business partnership, not a health benefit, and the cosmetics connection is a clue to what the ingredient was originally designed for: the skin, from the outside. A long development programme does not make the evidence stronger, and the studies the partnership is said to have produced are not cited on this page.
Mechanism of action
Verbascoside free radical scavenging
Verbascoside is a phenylethanoid glycoside that scavenges free radicals in test-tube and cell-culture assays, an activity linked to its catechol structure. The '5 times more active' figure has no citation on this page. Whether any of this happens in human tissue after swallowing a capsule has not been shown.
Multi-polyphenol synergy
Opextan contains verbascoside, hydroxytyrosol, tyrosol and isoacteoside together. One cell-culture study tested a three-compound combination and found it reduced UVB damage markers in skin cells (PMID 41266576), but no study compared the blend against single compounds in people, so calling it superior to isolates, or proving synergy, is not supported.
Skin barrier function support
The proposed idea is that olive polyphenols reduce oxidative damage to skin barrier lipids and support keratinocyte function. This is a hypothesis drawn from laboratory work on skin cells. The skin water and oil measurements the supplier reports come from a study that is not cited here, so this mechanism has no confirmed human result behind it.
UV-induced oxidative stress prevention
UV light generates reactive oxygen species that damage skin cells, and in a dish verbascoside and related olive polyphenols reduce that damage (PMID 18404597, PMID 41266576). Whether taking Opextan by mouth changes how a person's skin responds to sunlight has not been shown in any study cited here. Do not rely on it for sun protection.
Insulin sensitivity / glucose tolerance
It has been suggested that olive polyphenols affect blood sugar through insulin sensitivity and inflammation, but none of the references cited on this page measured glucose, insulin or any metabolic marker, in people or in cells. The 12-week study the page refers to is not cited and cannot be checked.
Clinical trials
This study is not among the references on this page, so it cannot be checked here. As described by the supplier: 67 healthy women chose for themselves whether to take Opextan 300 mg daily or nothing at all for 4 weeks. That means no randomisation, no placebo and no blinding, so expectation alone could explain any change. It was run by Indena, the company that sells the ingredient.
67 healthy women who selected their own group: Opextan 300 mg daily or no treatment, over 4 weeks. No placebo and no random assignment.
The supplier reports increases in skin water and oil content, fewer exfoliating cells, and changes in skin oxygen readings and blood flow. Because these results are not published in any source cited here, no numbers, statistics or comparison group can be checked. The further claims that Opextan promotes healthy skin aging or benefits cardiovascular risk factors go well beyond what a 4-week uncontrolled observation in 67 women could show, and no cited reference measured any cardiovascular outcome at all.
This is described as internal Kanebo research. It is not cited anywhere on this page and no published source is given for it, so the number of participants, the dose, the duration and whether there was any comparison group are all unknown. Unpublished company research is not evidence a buyer can weigh.
Unstated number of volunteers. No published details on dose, duration or control group are available.
The claimed results are reduced skin sensitivity to UV light after oral use, better oxidative stress readings, and less lipid peroxidation after applying the extract to the skin. None of this is published in any reference cited here, and the lipid peroxidation result comes from applying the extract topically, which says nothing about taking it by mouth. The added claim about preventing wrinkles and barrier damage is not supported by any human study on this page.
A 12-week study of olive pulp extract in people with impaired blood sugar control. It is not among the references on this page, so it cannot be checked here. Whether it used a placebo group, and what dose was given, are not stated.
15 people with impaired blood sugar control, over 12 weeks. That is a very small group, and results in people with a blood sugar problem do not carry over to healthy people.
Lower fasting blood sugar is reported after 12 weeks. No actual values, statistics or control group are available because the study is not cited here. With 15 participants and no verifiable publication, this cannot be treated as a demonstrated effect, and Opextan is not a treatment for high blood sugar or diabetes.